{"title": "ESC 2021: Bayer and Merck's Verquvo stakes its claim as a complementary heart failure treatment", "author": "Kevin Dunleavy", "url": "https://www.fiercepharma.com/pharma/esc-2021-a-different-class-bayer-and-merck-s-verquvo-stakes-its-claim-as-a-complementary", "hostname": "fiercepharma.com", "description": "Analysts don't see much potential for Bayer and Merck & Co.'s acute heart failure drug", "sitename": "FiercePharma", "date": "2021-08-28", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}